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OBJECTIVE — To further deﬁne clinical features associated with the syndrome of diabetes
and pancreatic exocrine dysfunction due to mutations in the carboxyl-ester lipase (CEL) gene
and to assess the effects of pancreatic enzyme substitution therapy.
RESEARCH DESIGN AND METHODS — Nine patients with CEL gene mutation,
exocrine deﬁciency, and diabetes were treated and followed for 30 months.
RESULTS — Treatment improved symptoms in seven of nine patients. Exocrine and endo-
crinefunctionassessedbyfecalelastaseandA1Cwerenotaffected,althoughfecallipidexcretion
was reduced. Vitamin E was low in all patients but increased with treatment (P  0.001 at 30
months) and improved in ﬁve subjects. A predominantly demyelinating neuropathy was seen in
a majority of patients, and carpal tunnel syndrome was common.
CONCLUSIONS — Pancreaticenzymesubstitutionalleviatedsymptomsandmalabsorption
and normalized vitamin E levels. Glycemic control was not signiﬁcantly affected. The CEL
syndrome seems associated with a demyelinating neuropathology.
Diabetes Care 31:1738–1740, 2008
W
e recently described the syn-
drome of diabetes and exocrine
pancreas dysfunction due to
mutations in the carboxyl-ester lipase
(CEL) gene (1,2). In the present study,
we assessed the effects of pancreatic en-
zyme substitution therapy (PEST) on
the endocrine and exocrine pancreatic
function of mutation carriers with exo-
crine insufﬁciency. In addition, neuro-
logical features associated with the
syndrome were reviewed.
RESEARCH DESIGN AND
METHODS— The patients were re-
cruited from Family 1 in the study by
Raeder et al. (1). Nine patients having di-
abetes and severely reduced fecal elastase
level were studied. Six additional patients
wereincludedforstudiesoftheneurolog-
ical features. The patients were given
standard PEST and followed for 30
months. An online appendix describes
the study design, protocol, determination
of exocrine dysfunction, and statistical
analysis (available at http://dx.doi.org/
10.2337/dc07-2217).
RESULTS— Baseline characteristics
of the nine patients are given in supple-
mentary Table 1, and the results after
treatment are shown in Fig. 1 and sup-
plementary Table 3. Two patients
dropped out of the study after 1 and 6
months, respectively, because of side
effects.
Sixpatientsidentiﬁedloosestoolsasa
major complaint. Seven patients reported
immediate improvement of abdominal
symptoms with treatment; however, the
treatment was unsatisfactory for the ma-
jority, and doses were subsequently
increased.
Baseline fecal elastase values were
10 g/g in all patients (compatible with
severe exocrine deﬁciency) and did not
change with treatment. A1C was moder-
ately high at baseline and did not change.
Pretreatment BMI was normal (median
[range] 24.0 [18–32] kg/m
2). Mean body
weight increased by 3 kg after 12 months
of treatment (P  0.01).
Seven patients had steathorrea at
baseline. At 30 months, fat excretion was
reduced in all four patients studied (from
35 [25–43] to 22 [12–37] g/day; P 
0.01). Vitamin E levels were low in all
patients but increased with treatment
(from 7.6 [2.8–10.1] to 13.2 [5.5–14.1]
mol/l; P  0.03) and normalized in ﬁve
of seven subjects after 12 months. Levels
of vitamins D and A were in the lower
normal range; vitamin D levels remained
unchanged, whereas vitamin A values in-
creased with PEST (from 1.1 [0.5–1.4] to
1.6 [1.3–1.7] mol/l; P  0.03). There
was a small but signiﬁcant increase in to-
tal, HDL, and LDL cholesterol but no
change in triglycerides. Osteoporosis was
diagnosed in three and osteopenia in two




supplementary Table 2. Electrophysio-
logical studies revealed peripheral neu-
ropathywithslowingofnerveconduction
consistent with a demyelinating etiology
in 10 of 15 subjects. Four had additional
electromyogrampathologysuggestingax-
onal damage. There was no correlation
between diabetes duration and symptom
severity. Five subjects had symptoms and
electrophysiologicalsignsofcarpaltunnel
syndrome.
Magnetic resonance imaging showed
multiple high-signal lesions in the cere-
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1738 DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008Figure 1—Effect of PEST treatment on selected clinical variables. A, B, D, F, and the upper part of C (A1C) show development of the variables for
each individual, whereas E and the bottom part of C show means  SD. A: Mean 72-h fat excretion was increased at baseline (normal values 7
g/day) and showed reduction after 1 week (NS), 12 months (NS), and 30 months of treatment (signiﬁcant reduction compared with baseline for the
four patients delivering stool at 30 months). B: Serum concentrations of the fat-soluble vitamin E were below the normal range in all patients at
baseline, reﬂecting malabsorption, but showed signiﬁcant increase from baseline at 6, 12, and 30 months. *P  0.001; **P  0.01. C: Glycemic
controlshownbyA1Cwasstabledespiteaslightbutsigniﬁcantweightgainduringtreatment.Thebottomofthegraph(F)showsmeaninsulindose
per day. D: The absolute weight change from baseline showed interindividual variation. Some subjects experienced a substantial weight gain. E: All
patients had remarkably low serum lipid values at baseline. There was a slight but signiﬁcant increase at 6, 12, and 30 months for total (F), HDL
(E),andLDL(Œ)cholesterol.Triglyceridelevels(‚)didnotchangesigniﬁcantly.*P0.05fortotal,HDL,andLDLcholesterolat12monthsand
fortotalandLDLcholesterolat30months.F:Bonemassdensity(BMD),asillustratedbyTscoreforL2–L5,wasincreasedorremainedstableafter
30 months of treatment in one-half of the subjects and had decreased slightly, as expected, in the others.
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patient (IV-11) consistent with her multi-
ple sclerosis diagnosis. Another subject
(III-9)hadscatteredhigh-signallesionsin
the supratentorial white matter, and his
daughter had one periventricular high-
signal lesion. They showed no clinical ev-
idence of central nervous system disease.
There was no effect on neurological
symptoms after 12 months of treatment.
CONCLUSIONS — PEST constitutes
themaintreatmentofmaldigestiondueto
exocrine pancreatic insufﬁciency. Symp-
tomatic effect in our patients was imme-
diate, probably due to improved
absorption, as indicated by decreased fe-
cal fat excretion and normalization of se-
rum vitamin E. It is well recognized that
fat excretion is seldom normalized by
PEST. Exocrine function, as assessed by
fecal elastase, did not improve. This was
anticipated; the very low elastase values
probably reﬂect end-stage pancreatic dis-
ease. Glycemic control remained un-
changed,conﬁrmingrecentresultsfroma
study examining enzyme replacement in
type1diabeteswithexocrinedysfunction
(3).
A high prevalence of exocrine insufﬁ-
ciency has been reported in both type 1
andtype2diabetes(4)andinHNF1Aand
HNF1B maturity-onset diabetes of the
young (5,6). Claims that this deﬁciency is
moderate, nonprogressive, and therefore
clinically irrelevant (7) are contradicted by
the ﬁnding of pathologically high fat excre-
tion in diabetic patients with fecal elastase
deﬁciency (4). An independent correlation
between fecal elastase levels and, respec-
tively, glycemic control and residual -cell
function has been reported (8).
A predominantly demyelinating neu-
ropathy was present in 10 of 15 patients.
Onlyfourpatientshadevidenceofaxonal
damage. Neuropathy is common in dia-
betes, particularly in the presence of
chronically poor glycemic control, but it
is typically in the form of axonopathy (9),
although demyelinating changes are de-
scribed (10). Our patients exhibited few
signs of long-standing hyperglycemia
(supplemenary Table 1). No correlation
between disease duration and presence of
neuropathy was seen. Five patients had
carpal tunnel syndrome, conﬁrming the
association between diabetes and com-
pression neuropathy.
Vitamin E deﬁciency affects both the
central and peripheral nervous systems
(11). The associated peripheral neuropa-
thy is most often axonal (11), although
demyelinating neuropathy also occurs
(12).VitaminElevelsimprovedfollowing
treatment, but the electrophysiological
ﬁndings and patients’ sensory symptoms
did not improve. This result is consistent
withthatinprimaryvitaminEdeﬁciency,
in which supplementation, at best, stabi-
lizes the condition. Fat malabsorption
and/or chronic vitamin E deﬁciency may
contribute to the neurological manifesta-
tions seen in Family 1.
In conclusion, demyelinating periph-
eralneuropathyappearstobeaconsistent
feature of the CEL syndrome. Whether
this is directly connected to the mutation
or secondary to malabsorption and/or di-
abetes is unclear and warrants further
study. PEST alleviated symptoms, re-
duced fecal fat excretion, and improved
vitamin A and E status but did not im-
prove glycemic control. Vitamin status
shouldbecheckedinpatientswithdiabe-
tes and fecal elastase deﬁciency because it
may indicate treatable malabsorption.
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